Epilepsy Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Department of Neurology and Department of Population Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Epilepsia. 2022 Oct;63(10):2491-2506. doi: 10.1111/epi.17350. Epub 2022 Jul 17.
Epilepsy surgery is the treatment of choice for patients with drug-resistant seizures. A timely evaluation for surgical candidacy can be life-saving for patients who are identified as appropriate surgical candidates, and may also enhance the care of nonsurgical candidates through improvement in diagnosis, optimization of therapy, and treatment of comorbidities. Yet, referral for surgical evaluations is often delayed while palliative options are pursued, with significant adverse consequences due to increased morbidity and mortality associated with intractable epilepsy. The Surgical Therapies Commission of the International League Against Epilepsy (ILAE) sought to address these clinical gaps and clarify when to initiate a surgical evaluation. We conducted a Delphi consensus process with 61 epileptologists, epilepsy neurosurgeons, neurologists, neuropsychiatrists, and neuropsychologists with a median of 22 years in practice, from 28 countries in all six ILAE world regions. After three rounds of Delphi surveys, evaluating 51 unique scenarios, we reached the following Expert Consensus Recommendations: (1) Referral for a surgical evaluation should be offered to every patient with drug-resistant epilepsy (up to 70 years of age), as soon as drug resistance is ascertained, regardless of epilepsy duration, sex, socioeconomic status, seizure type, epilepsy type (including epileptic encephalopathies), localization, and comorbidities (including severe psychiatric comorbidity like psychogenic nonepileptic seizures [PNES] or substance abuse) if patients are cooperative with management; (2) A surgical referral should be considered for older patients with drug-resistant epilepsy who have no surgical contraindication, and for patients (adults and children) who are seizure-free on 1-2 antiseizure medications (ASMs) but have a brain lesion in noneloquent cortex; and (3) referral for surgery should not be offered to patients with active substance abuse who are noncooperative with management. We present the Delphi consensus results leading up to these Expert Consensus Recommendations and discuss the data supporting our conclusions. High level evidence will be required to permit creation of clinical practice guidelines.
癫痫手术是耐药性癫痫患者的首选治疗方法。对于被认为是合适手术候选者的患者,及时评估手术候选资格可以挽救生命,并且通过改善诊断、优化治疗和治疗合并症,也可以增强非手术候选者的护理。然而,由于与难治性癫痫相关的发病率和死亡率增加,手术评估的转诊常常被延迟,同时仍在寻求姑息性治疗方案,这带来了严重的不良后果。国际抗癫痫联盟(ILAE)的外科治疗委员会旨在解决这些临床差距并明确何时开始手术评估。我们与来自 28 个国家的 61 名癫痫专家、癫痫神经外科医生、神经病学家、神经精神科医生和神经心理学家进行了德尔菲共识过程,他们的中位数实践经验为 22 年。在三轮德尔菲调查中,评估了 51 个独特的情况后,我们得出了以下专家共识建议:(1)对于每个耐药性癫痫患者(最多 70 岁),一旦确定耐药性,无论癫痫持续时间、性别、社会经济地位、发作类型、癫痫类型(包括癫痫性脑病)、定位和合并症(包括严重的精神合并症,如非癫痫性癫痫发作[PNES]或药物滥用),只要患者能够配合管理,都应提供手术评估的转诊;(2)对于没有手术禁忌症的耐药性老年癫痫患者,以及在 1-2 种抗癫痫药物(ASM)下无发作但在非语言皮质中有脑病变的患者(成人和儿童),应考虑进行手术转诊;(3)对于不配合管理的有活动性药物滥用的患者,不应提供手术转诊。我们展示了导致这些专家共识建议的德尔菲共识结果,并讨论了支持我们结论的数据。需要高级别的证据来制定临床实践指南。